Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL

A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is... ORIGINAL ARTICLE A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL James Symanowski, PhD,* Nicholas Vogelzang, MD,* Leigh Zawel, PhD,† Peter Atadja, PhD,† Harvey Pass, MD,‡ and Sunil Sharma, MD* Key Words: Mesothelioma, Histone deacetylase inhibitors, apopto- Purpose: Tumor necrosis factor-alpha-related apoptosis-inducing sis, Tumor necrosis factor-alpha-related apoptosis-inducing ligand. ligand (TRAIL) is a member of tumor necrosis factor family and it (J Thorac Oncol. 2009;4: 149–160) is important for ligand induced apoptosis in tumor cells. TRAIL has been shown to be synergistic with a variety of chemotherapies and targeted agents. In the study, a combination of TRAIL and a histone umor necrosis factor-alpha-related apoptosis-inducing li- deacetylase inhibitor LBH589 was studied in mesothelioma cell Tgand (TRAIL) is a member of tumor necrosis factor lines. (TNF) superfamily and exhibits antitumor activity in a vari- Experimental Design: Five mesothelioma cell lines and two normal 1,2 1,2 ety of tumor cells. TRAIL signals primarily through two cell lines were tested for cell growth inhibition and apoptosis using receptors—DR4 and DR5 that carry a cytoplasmic death high-throughput assays in the presence of LBH589, TRAIL and a domain. Upon binding to its receptors, TRAIL induces http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL

Sharma, Sunil
Journal of Thoracic Oncology , Volume 4 (2) – Feb 1, 2009
Download PDF
12 pages

Loading next page...
 
/lp/wolters-kluwer-health/a-histone-deacetylase-inhibitor-lbh589-downregulates-xiap-in-sm9ivLhg0c

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e318194f991
pmid
19179889
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL James Symanowski, PhD,* Nicholas Vogelzang, MD,* Leigh Zawel, PhD,† Peter Atadja, PhD,† Harvey Pass, MD,‡ and Sunil Sharma, MD* Key Words: Mesothelioma, Histone deacetylase inhibitors, apopto- Purpose: Tumor necrosis factor-alpha-related apoptosis-inducing sis, Tumor necrosis factor-alpha-related apoptosis-inducing ligand. ligand (TRAIL) is a member of tumor necrosis factor family and it (J Thorac Oncol. 2009;4: 149–160) is important for ligand induced apoptosis in tumor cells. TRAIL has been shown to be synergistic with a variety of chemotherapies and targeted agents. In the study, a combination of TRAIL and a histone umor necrosis factor-alpha-related apoptosis-inducing li- deacetylase inhibitor LBH589 was studied in mesothelioma cell Tgand (TRAIL) is a member of tumor necrosis factor lines. (TNF) superfamily and exhibits antitumor activity in a vari- Experimental Design: Five mesothelioma cell lines and two normal 1,2 1,2 ety of tumor cells. TRAIL signals primarily through two cell lines were tested for cell growth inhibition and apoptosis using receptors—DR4 and DR5 that carry a cytoplasmic death high-throughput assays in the presence of LBH589, TRAIL and a domain. Upon binding to its receptors, TRAIL induces

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Feb 1, 2009

References

  • Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
    Almasan
  • Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
    Pitti
  • Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression
    Eggert
  • Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation
    Lee
  • Differential susceptibility to TRAIL of normal versus malignant human urothelial cells
    Steele
  • Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells
    Vogler
  • APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy
    Bucur
  • Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells
    Guo
  • Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid
    Krug
  • Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
    Chou